이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

암 치료 선택을 위한 비침습적 종합 게놈 프로파일링의 임상적 유용성을 평가하기 위한 액체 생검 정보 정밀 종양학 연구

Overall, this project has three main goals: first, to ascertain the feasibility of the approach and identify whether liquid biopsies can detect actionable mutations that can be utilized to generate precision oncology treatment recommendations. Second, the investigators will investigate whether enacting upon MTB recommendations would improve outcomes in terms of progression-free and overall survival. Third, the investigators aim to determine if molecular profiling via serial plasma tests after initiation of chemotherapy or other targeted treatment is sufficient to determine whether or not a patient is responding to therapy.

연구 개요

상세 설명

  1. Quality assurance plan that addresses data validation and registry procedures, including any plans for site monitoring and auditing.

    All information will be collected on study-specific case report forms (CRFs) hosted in Redcap and/or directly entered into a study database. The following measures will be taken to protect patient information:

    • The database will be password protected; only authorized staff may enter and view project data.
    • Passwords and system IDs will not be shared.
    • Physical security of the workstations/files will be maintained. Workstations with the database open will not be left unattended.
    • Staff will be trained on the data entry system and on security procedures.
    • The study data will be reviewed/monitored by the Sidney Kimmel Comprehensive Cancer Center Clinical Research Office and the Cancer Center Safety committee.
  2. Data checks to compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry.

    Data checks will be performed per SKCCC SOP DM-01-04 CRF Documentation Standards.

    Case Report Form (CRF): A printed, optical, or electronic document designed to record all of the protocol-required information to be reported to the sponsor on each trial subject. ICH GCP 1.11 Source Documents: Original documents, data, and records (e.g., hospital records, clinical and office charts, laboratory notes, memoranda, subjects' diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate and complete, microfiches, photographic negatives, microfilm or magnetic media, x-rays, subject files, and records kept at the pharmacy, at the laboratories, and at the medicotechnical departments involved in the clinical trial). ICH GCP 1.52

  3. Source data verification to assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources (for example, medical records, paper or electronic case report forms, or interactive voice response systems).

    All study data will be reviewed for completeness and accuracy by the Protocol Chair who will ensure the completeness and accuracy of the data generated. The designated research coordinator(s) participating in this project will collect clinical information associated with each participant. Such data could include, but is not limited to: medical record number, age, sex, treatment history, circulating tumor markers, tumor size, tumor grade, tumor receptor status, pathology report, smoking history, hormonal history, concomitant medications, and parity. Such information will be retrieved from existing clinical databases/EMR (e.g., EPIC) and patient questionnaire information, and may also include electronic scheduling and prescription systems.

    Follow-up information will be collected by review of the medical records. In addition, participants may be reached by phone to help with any questions or clarifications, or additional follow-up requirements.

  4. Data dictionary that contains detailed descriptions of each variable used by the registry, including the source of the variable, coding information if used (for example, World Health Organization Drug Dictionary, MedDRA), and normal ranges if relevant.

    Source for data dictionary is included in Botsis et al., JCO CCI, 2023, in press.

  5. Standard Operating Procedures to address registry operations and analysis activities, such as patient recruitment, data collection, data management, data analysis, reporting for adverse events, and change management.

    These activities will be carried out in compliance with the study protocol and Good Clinical Practice principles. Information regarding study conduct and progress will be reported to our local Institutional Review Board (IRB) per current institutional standards. The study will undergo routine annual review as per current institutional standards.

  6. Sample size assessment to specify the number of participants or participant years necessary to demonstrate an effect.

    We will recruit 150 patients with solid tumors including non-adenocarcinoma NSCLC, small-cell lung cancer, neuroendocrine lung cancer, mesothelioma, esophageal cancer, breast cancer and head and neck cancer. Based on the liquid biopsy assay's analytical performance we expect to detect tumor-specific mutations in >85% of the individuals. We expect to complete the accrual in 1.5 years. The analysis is primarily descriptive for this feasibility study. A sample size of 150 patients will provide reasonable confidence around the observed estimate of proportions, e.g. percent of patients with variants of clinical significance. The width of 95% confidence interval will be narrower than 16.5%.

  7. Plan for missing data to address situations where variables are reported as missing, unavailable, non-reported, uninterpretable, or considered missing because of data inconsistency or out-of-range results.

    Missing data will be excluded from downstream analyses.

  8. Statistical analysis plan describing the analytical principles and statistical techniques to be employed in order to address the primary and secondary objectives, as specified in the study protocol or plan.

    1. Analysis of Primary Objectives:

      The primary objectives are to determine the number and prevalence of variants with clinical significance across different levels of evidence (stratified by gene and alteration type), as described above and to determine the percentage of patients with an MTB treatment recommendation accordingly. Descriptive analysis will be performed to estimate the percentage of patients that harbor variants with clinical significance detected in ctDNA samples, along with 95% confidence intervals. The percentage of patients with an MTB treatment recommendation tailored to an actionable alteration according to the mutation profiles detected by liquid biopsies, and percentage of patients treated according to MTB recommendation will be estimated. The days from collection of liquid biopsies to MTB recommendation, and days from MTB recommendation to treatment initiation will be summarized by mean, median, standard deviation and range. We plan to summarize the data after every 30 patients.

    2. Analysis of Secondary Objectives:

Time to subsequent cancer therapy is the time from initiation of treatment to the start of next cancer therapy according to treating physician's decision. Progression-free survival (PFS) is the time from initiation of therapy to radiographic progression per RECIST, clinical progression or worsening disease per treating physician's assessment. Overall survival (OS) is the time from initiation of therapy to death due to any cause. PFS and OS will be characteristics by Kaplan-Meier method, among patients who do and do not have an MTB recommendation, and for patients who do and do not receive recommended treatment.

Descriptive analysis will be performed to report the frequency of MTB-based treatment recommendations by therapeutic class (standard of care, clinical trial, off-label use), and the deviations from treatment recommendations and reasons (clinical deterioration, other protocol, patient ineligible, off-label treatment unavailable, clinical trial not feasible (e.g. physical distance), clinical trial not recruiting, physician's decision, patient's choice, etc.) The concordance of detected alterations obtained through liquid biopsy analyses at baseline compared to time-matched or archival tissue specimens will be summarized and quantified using Kappa statistics.

Descriptive analyses will also be performed to determine the cell-free DNA yield and ctDNA amount by tumor type obtained through liquid biopsy analyses. Additionally, the assay success rate by tumor type and by pre-analytical variables will be performed across minimum technical data elements, including:

  • Blood collection tube type
  • Sample composition
  • Shipping temperature
  • Blood fractionalization method
  • Time to fractionation
  • Analyte isolation method
  • Time to freezer
  • Storage temperature
  • Concentration: cellular concentration or molecular concentration
  • Assay method
  • Time to assay

연구 유형

관찰

등록 (추정된)

200

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Maryland
      • Baltimore, Maryland, 미국, 21287

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

해당 없음

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Patients with solid tumors, including esophageal cancer, non-adenocarcinoma NSCLC, small-cell lung cancer, head & neck cancer, mesothelioma, breast cancer and lung neuroendocrine cancer.

설명

Inclusion Criteria:

  • ECOG performance status of 0-1.
  • Patients with solid tumors, including esophageal cancer, non-adenocarcinoma NSCLC, small-cell lung cancer, head & neck cancer, mesothelioma, breast cancer and lung neuroendocrine cancer.
  • Patients who can provide whole blood collection to meet minimum of 20-30ml of blood at baseline, within 1-3 weeks from treatment initiation, at first radiographic imaging and at progression. Acquisition of an archival or time-matched tumor tissue specimen which meets the minimum sample input requirements (at least 20% tumor content and 100 ng) is preferred but not required.
  • Patients with metastatic disease will have progressed on the most recent treatment prior to enrollment. Patient can also be enrolled if their oncologist believes progression is imminent and test results would be used to inform next line of therapy. Patients considered for first-line SOC therapeutic options may be enrolled if the clinical efficacy of these therapies is not encouraging.
  • Patients must have disease evaluable for progression assessment; measurable disease is not required to participate in the study.
  • Able to voluntarily provide informed consent.

Exclusion Criteria:

  • Women who are known to be pregnant
  • History of another primary malignancy in the last 5 years prior to registration unless approved by the Protocol Chair/designee. Patients with prior history of in situ cancer or basal or localized squamous cell skin cancer are eligible.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: OTHER
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
개입 / 치료
Oncology Patients

All participants in the study.

Use of liquid biopsy to evaluate the clinical utility of non-invasive comprehensive genomic profiling for cancer treatment selection.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Prevalence of variants in ctDNA with clinical significance across different levels of evidence
기간: Up to 2 years after enrollment

To determine the prevalence of variants in ctDNA with clinical significance across different levels of evidence (stratified by gene and alteration type). In cases where tumor next-generation sequencing has been performed, tumor mutational profiles will be evaluated in conjunction with the liquid biopsy results.

Up to 2 years after enrollment
Percentage of patients with a molecular tumor board (MTB) treatment recommendation
기간: Up to 2 years after enrollment

To determine the percentage of patients with a molecular tumor board (MTB) treatment recommendation tailored to an actionable alteration according to the mutation profiles detected by liquid biopsies.

Up to 2 years after enrollment
Percentage of patients treated according to MTB recommendation
기간: Up to 2 years after enrollment

To determine percentage of patients treated according to MTB recommendation.

Up to 2 years after enrollment
Turnaround time from collection of liquid biopsy to MTB recommendation
기간: Up to 2 years after enrollment

To determine turnaround time from collection of liquid biopsy to MTB recommendation.

Up to 2 years after enrollment
Time from MTB recommendation to treatment initiation
기간: Up to 2 years after enrollment

To determine the time from MTB recommendation to treatment initiation.

Up to 2 years after enrollment

2차 결과 측정

결과 측정
측정값 설명
기간
Time to cancer therapy for patients who are treated according to MTB recommendation
기간: Up to 2 years after enrollment

To determine time to subsequent cancer therapy for patients who are treated according to MTB recommendation.

Up to 2 years after enrollment
Time to cancer therapy for patients who are not treated according to MTB recommendation
기간: Up to 2 years after enrollment

To determine time to subsequent cancer therapy for patients who are not treated according to MTB recommendation.

Up to 2 years after enrollment
Progression free-survival of patients who are treated according to the MTB recommendations
기간: Up to 2 years after enrollment

To determine the progression free-survival of patients who are treated according to the MTB recommendations.

Up to 2 years after enrollment
Progression free-survival of patients who are not treated according to the MTB recommendations
기간: Up to 2 years after enrollment

To determine the progression free-survival of patients who are not treated according to the MTB recommendations.

Up to 2 years after enrollment
Overall survival of patients who do receive treatment according to the MTB recommendations
기간: Up to 2 years after enrollment

To determine the overall survival of patients who do receive treatment according to the MTB recommendations.

Up to 2 years after enrollment
Overall survival of patients who do not receive treatment according to the MTB recommendations
기간: Up to 2 years after enrollment

To determine the overall survival of patients who do not receive treatment according to the MTB recommendations.

Up to 2 years after enrollment
MTB-based treatment recommendations stratified by therapeutic class
기간: Up to 2 years after enrollment

To determine MTB-based treatment recommendations stratified by therapeutic class (SOC, clinical trials, off-label use).

Up to 2 years after enrollment
Proportion of deviations from treatment recommendations
기간: Up to 2 years after enrollment

To determine the proportion of deviations from treatment recommendations.

Up to 2 years after enrollment
Reasons for deviations from treatment recommendations
기간: Up to 2 years after enrollment

To determine the reasons (clinical deterioration, other protocol, patient ineligible, off-label treatment unavailable, clinical trial not feasible (e.g. physical distance), clinical trial not recruiting, physician's decision, patient's choice, etc.) for deviations from treatment recommendations.

Up to 2 years after enrollment
Concordance of detected alterations obtained through liquid biopsy analyses
기간: Up to 2 years after enrollment

To determine the concordance of detected alterations obtained through liquid biopsy analyses at baseline compared to next generation sequencing of time-matched or archival tissue specimens.

Up to 2 years after enrollment
cfDNA yield obtained
기간: Up to 2 years after enrollment

To determine the cfDNA yield obtained through liquid biopsy analyses by tumor type.

Up to 2 years after enrollment
ctDNA amount obtained
기간: Up to 2 years after enrollment

To determine the ctDNA amount obtained through liquid biopsy analyses by tumor type.

Up to 2 years after enrollment
Liquid biopsy assay success rate
기간: Up to 2 years after enrollment

To determine the liquid biopsy assay success rate by tumor type and by pre-specified pre-analytical variables.

Up to 2 years after enrollment

기타 결과 측정

결과 측정
측정값 설명
기간
Correlation of changes in ctDNA levels with radiologic response
기간: Up to 2 years after enrollment

To determine the correlation of changes in ctDNA levels with radiologic response by RECIST.

Up to 2 years after enrollment
Correlation of changes in ctDNA levels to progression-free survival
기간: Up to 2 years after enrollment

To determine the correlation of changes in ctDNA levels to progression-free survival.

Up to 2 years after enrollment
Correlation of changes in ctDNA levels to overall survival
기간: Up to 2 years after enrollment

To determine the correlation of changes in ctDNA levels to overall survival.

Up to 2 years after enrollment

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Valsamo Anagnostou, MD, PhD, Johns Hopkins University

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 1월 27일

기본 완료 (추정된)

2027년 9월 1일

연구 완료 (추정된)

2027년 9월 1일

연구 등록 날짜

최초 제출

2022년 10월 14일

QC 기준을 충족하는 최초 제출

2022년 10월 14일

처음 게시됨 (실제)

2022년 10월 19일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 2일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • J2271
  • IRB00333925 (기타 식별자: Johns Hopkins IRB)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다